Enanta Pharmaceuticals has announced the filing of a patent infringement suit against Pfizer in the Unified Patent Court of the European Union. The suit concerns the alleged infringement of European Patent No. EP 4 051 265, which involves coronavirus protease inhibitors. Enanta is seeking a determination of liability related to the manufacture, use, and sale of Pfizer's COVID-19 antiviral, Paxlovid. The patent is the European counterpart of a U.S. patent involved in ongoing litigation between the two companies. A hearing in the UPC is expected to take place within 12 months, with a decision to follow shortly thereafter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.